Med BioGene Inc. (MBI)

Med BioGene Inc. is a life science corporation dedicated to managing the license and rights to LungExpress Dx, a prognostic genomic-based test for non-small-cell lung cancer.



Contact Information:
Business Address: | #510 - 580 Hornby Street Vancouver, British Columbia V6C 3B6 |
Mailing Address: | #510 - 580 Hornby Street Vancouver, British Columbia V6C 3B6 |
Phone: | 604 827-5100 |
Email: | ebroshko@medbiogene.com |
Website: | - |
Company Details:
Market Cap: | - |
Year of Inc: | April 28, 2006 |
Year Ends: | December 31, 2012 |
Sector: | - |
Industry: | consumer products - biotechnology/pharmaceuticals |
Employees: | - |
CEO: | - |
Audited annual financial statements - English April 30, 2012
52-109FV1 - Certification of annual filings - CEO (E) April 30, 2012
Med Biogene Inc. Stock (CVE:MBI) Advanced, But at What Cost? March 07, 2011
In the world of business there is nothing certain. Risk is almost everywhere. It depends on you and your leader's abilities to minimize it. If you are smart enough, you will probably avoid signing deals that might eventually bring you more losses than short-time immediate gains. However, this is not always so simple as it seems. The managers of Med Biogene Inc. ( CVE:MBI ) have made up their minds. Last Tuesday, they announced their decision to enter a strategic agreement with Precision...read more
Post # | Subject | Re | Name | Date |
---|---|---|---|---|
There are no comments. |
someone replies to your post?